- Home
- DXR vs TVGN Comparison
DXR vs TVGN Comparison
Compare DXR & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DXR | TVGN |
|---|---|---|
| Founded | 1970 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.4M | 63.9M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | DXR | TVGN |
|---|---|---|
| Price | $9.02 | $4.98 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.5K | ★ 37.3K |
| Earning Date | 02-27-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $1,446,345.00 | N/A |
| Revenue This Year | $44,935.22 | N/A |
| Revenue Next Year | $74.79 | N/A |
| P/E Ratio | $33.83 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.10 | $0.14 |
| 52 Week High | $14.76 | $10.76 |
Technical Indicators
Market Signals| Indicator | DXR | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 19.66 | 60.36 |
| Support Level | $8.45 | $0.47 |
| Resistance Level | $9.37 | $5.64 |
| Average True Range (ATR) | 0.49 | 0.47 |
| MACD | -0.10 | -0.25 |
| Stochastic Oscillator | 7.53 | 59.47 |
Price Performance
Historical ComparisonAbout DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About TVGN Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.